| Association of obesity with worse disease severity in rheumatoid arthritis as well as with comorbidities: a long‐term followup from disease onset S Ajeganova, ML Andersson, I Hafström, BARFOT Study Group Arthritis care & research 65 (1), 78-87, 2013 | 303 | 2013 |
| Late‐onset neutropenia following rituximab therapy in rheumatic diseases: Association with B lymphocyte depletion and infections D Tesfa, S Ajeganova, H Hägglund, B Sander, B Fadeel, I Hafström, ... Arthritis & Rheumatism 63 (8), 2209-2214, 2011 | 186 | 2011 |
| Sustained remission in rheumatoid arthritis: latest evidence and clinical considerations S Ajeganova, T Huizinga Therapeutic advances in musculoskeletal disease 9 (10), 249-262, 2017 | 158 | 2017 |
| Disease factors in early rheumatoid arthritis are associated with differential risks for cardiovascular events and mortality depending on age at onset: a 10-year observational … S Ajeganova, MLE Andersson, J Frostegård, I Hafström The Journal of rheumatology 40 (12), 1958-1966, 2013 | 118 | 2013 |
| The association between anti-carbamylated protein (anti-CarP) antibodies and radiographic progression in early rheumatoid arthritis: a study exploring replication and the added … S Ajeganova, HW Van Steenbergen, MK Verheul, K Forslind, I Hafström, ... Annals of the rheumatic diseases 76 (1), 112-118, 2017 | 108 | 2017 |
| Disease-modifying antirheumatic drug-free sustained remission in rheumatoid arthritis: an increasingly achievable outcome with subsidence of disease symptoms S Ajeganova, HW Van Steenbergen, JAB Van Nies, LE Burgers, ... Annals of the rheumatic diseases 75 (5), 867-873, 2016 | 105 | 2016 |
| Anticitrullinated protein antibodies and rheumatoid factor are associated with increased mortality but with different causes of death in patients with rheumatoid arthritis: a … S Ajeganova, JH Humphreys, MK Verheul, HW Van Steenbergen, ... Annals of the rheumatic diseases 75 (11), 1924-1932, 2016 | 91 | 2016 |
| Seronegative and seropositive RA: alike but different? S Ajeganova, TWJ Huizinga Nature Reviews Rheumatology 11 (1), 8-9, 2015 | 89 | 2015 |
| Carotid atherosclerosis, disease measures, oxidized low-density lipoproteins, and atheroprotective natural antibodies for cardiovascular disease in early rheumatoid arthritis … S Ajeganova, ULF de Faire, T Jogestrand, J Frostegård, I Hafström The Journal of rheumatology 39 (6), 1146-1154, 2012 | 88 | 2012 |
| Low-dose prednisolone treatment of early rheumatoid arthritis and late cardiovascular outcome and survival: 10-year follow-up of a 2-year randomised trial S Ajeganova, B Svensson, I Hafström, BARFOT Study Group BMJ open 4 (4), e004259, 2014 | 77 | 2014 |
| Smoking is associated with the concurrent presence of multiple autoantibodies in rheumatoid arthritis rather than with anti-citrullinated protein antibodies per se: a … TJ van Wesemael, S Ajeganova, J Humphreys, C Terao, A Muhammad, ... Arthritis research & therapy 18, 1-10, 2016 | 68 | 2016 |
| Rheumatoid arthritis phenotype at presentation differs depending on the number of autoantibodies present V Derksen, S Ajeganova, LA Trouw, AHM van der Helm-van Mil, ... Annals of the rheumatic diseases 76 (4), 716-720, 2017 | 57 | 2017 |
| The effects of rheumatoid factor and anticitrullinated peptide antibodies on bone erosions in rheumatoid arthritis HW Van Steenbergen, S Ajeganova, K Forslind, B Svensson, ... Annals of the rheumatic diseases 74 (1), e3-e3, 2015 | 52 | 2015 |
| Influence of age and sex on disease course and treatment in rheumatoid arthritis J Nilsson, MLE Andersson, I Hafström, B Svensson, K Forslind, ... Open access rheumatology: research and reviews, 123-138, 2021 | 45 | 2021 |
| Patients with SLE have higher risk of cardiovascular events and mortality in comparison with controls with the same levels of traditional risk factors and intima-media measures … S Ajeganova, I Hafström, J Frostegård Lupus Science & Medicine 8 (1), e000454, 2021 | 42 | 2021 |
| IgM antibodies against phosphorylcholine promote polarization of T regulatory cells from patients with atherosclerotic plaques, systemic lupus erythematosus and healthy donors J Sun, SL Lundström, B Zhang, RA Zubarev, J Steuer, P Gillgren, ... Atherosclerosis 268, 36-48, 2018 | 42 | 2018 |
| Effect of biological therapy on levels of atheroprotective antibodies against phosphorylcholine and apolipoproteins in rheumatoid arthritis: a one-year study S Ajeganova, R Fiskesund, U de Faire, I Hafström, J Frostegård Clinical and Experimental Rheumatology-Incl Supplements 29 (6), 942, 2011 | 42 | 2011 |
| The prevalence of ACPA is lower in rheumatoid arthritis patients with an older age of onset but the composition of the ACPA response appears identical DM Boeters, L Mangnus, S Ajeganova, E Lindqvist, B Svensson, ... Arthritis research & therapy 19, 1-10, 2017 | 32 | 2017 |
| Persistently active disease is common in patients with rheumatoid arthritis, particularly in women: a long-term inception cohort study B Svensson, MLE Andersson, K Forslind, S Ajeganova, I Hafström, ... Scandinavian Journal of Rheumatology 45 (6), 448-455, 2016 | 31 | 2016 |
| Longitudinal levels of apolipoproteins and antibodies against phosphorylcholine are independently associated with carotid artery atherosclerosis 5 years after rheumatoid … S Ajeganova, C Ehrnfelt, R Alizadeh, M Rohani, T Jogestrand, I Hafström, ... Rheumatology 50 (10), 1785-1793, 2011 | 31 | 2011 |
